RVMD (Revolution Medicines) Pangali Forward P/E

Simbol resmi perusahaan Revolution Medicines, Inc. (RVMD)

The high barrier to entry in the targeted oncology therapy sector is driven by complex patenting and costly research. The expected P/E multiple valuation for Revolution Medicines (RVMD) clearly illustrates these processes, where 0.00 serves as the current metric level. Growth potential relies on the commercialization of RAS protein inhibitors for gastrointestinal and lung therapies, as well as positive clinical trial results.

Revolution Medicines, Inc. - Pangali Forward P/E RVMD (periode 04.07.2022 - 17.11.2026)

Ringkesan rincian data analitis revmed.com (RVMD)

- rega saiki lan proyeksi nilai saham:
Pambiji fundamental:revmed.com
Produk merek Revolution Medicines

Revolution Medicines integrates AI modeling and synthesis automation to accelerate the development of oncology drugs, which directly impacts future profitability. By analyzing the forward P/E ratio for Revolution Medicines (RVMD), an investor assesses the current stock price relative to the expected net income in one year; a sharp increase in this multiple signals inflated market expectations, while a moderate valuation confirms the fundamental resilience of the business.

Pesaing Revolution Medicines (RVMD)

Pangali Forward P/E ONC|HALO (Halozyme Inc.) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E AAPG (ascentage.com)|CGON - Prakiraan rega marang bathi|URGN: Prakiraan rega marang bathi|BCAX - Pangali Forward P/E|Personalis Corp (PSNL) - Rega marang bathi mangsa ngarep|Erasca Corp - Pangali mangsa ngarep rega marang bathi|DCTH (Delcath Systems Inc) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Y-mAbs Therapeutics, Inc. YMAB|Pangali Forward P/E AURA|Prakiraan rega marang bathi Candel Therapeutics, Inc. CADL|Pangali Forward P/E ARAY (Accuray, Inc.)|SELLAS Life Sciences - Rega marang bathi mangsa ngarep|ACTU: Prakiraan rega marang bathi|Citius Oncology, Inc. - Rasio kapitalisasi marang bathi mangsa ngarep|HURA (TuHURA Biosciences) - Prakiraan rega marang bathi|TARA: Rasio kapitalisasi marang bathi mangsa ngarep|Prakiraan rega marang bathi FATE|WHWK: Pangali mangsa ngarep rega marang bathi|Prakiraan rega marang bathi TCRX (TScan Therapeutics Inc)|Kapitalisasi marang proyeksi bathi Champions Oncology Inc|Pangali Forward P/E XBIT (XBiotech Inc.)|Pangali mangsa ngarep rega marang bathi CVM|OS Therapies Inc. - Pangali Forward P/E|RADX - Pangali Forward P/E|ARTV: Pangali Forward P/E|ANL: Rasio kapitalisasi marang bathi mangsa ngarep|Prakiraan rega marang bathi VERU|TPST: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep xiliotx.com (XLO)|Renovaro - Rasio rega marang bathi mangsa ngarep|Rega marang bathi mangsa ngarep Mural Oncology MURA|KAPA - Prakiraan rega marang bathi|OKUR - Rega marang bathi mangsa ngarep|GDTC - Pangali Forward P/E|Curis, Inc. (CRIS) - Rega marang bathi mangsa ngarep|Prakiraan rega marang bathi Apollomics, Inc.|Prakiraan rega marang bathi THAR|Rasio rega marang bathi mangsa ngarep ADVB (Advanced Biomed)|Prakiraan rega marang bathi GNPX (Genprex, Inc)|CLDI: Rasio rega marang bathi sing dikarepake|Rega marang bathi mangsa ngarep sunshinebiopharma.com SBFM|XBIO - Prakiraan rega marang bathi|SLRX: Prakiraan rega marang bathi|Purple Biotech - Rasio kapitalisasi marang bathi mangsa ngarep|American Oncology Network (AONC) - Rega marang bathi mangsa ngarep|Rasio rega marang bathi mangsa ngarep BGNE|Prakiraan rega marang bathi CKPT|Rega marang bathi mangsa ngarep ELEV|Pangali Forward P/E ICAD|Pangali Forward P/E Ikena Oncology Inc. (IKNA)|Pangali Forward P/E NTBL (Notable Labs Ltd)|Kapitalisasi marang proyeksi bathi Viracta Therapeutics (VIRX)|MOR: Prakiraan rega marang bathi|NAYA (NAYA Bio) - Rasio rega marang bathi mangsa ngarep|AAPGV: Pangali Forward P/E